Limbitrol Ds

Depression, Enterocolitis, Anxiety Disorders + 6 more
Treatment
8 FDA approvals
20 Active Studies for Limbitrol Ds

What is Limbitrol Ds

ChlordiazepoxideThe Generic name of this drug
Treatment SummaryChlordiazepoxide is a medication used to treat anxiety, seizures, and memory loss. It can also be used to help with alcohol withdrawal symptoms.
Libraxis the brand name
image of different drug pills on a surface
Limbitrol Ds Overview & Background
Brand Name
Generic Name
First FDA Approval
How many FDA approvals?
Librax
Chlordiazepoxide
1966
112

Approved as Treatment by the FDA

Chlordiazepoxide, otherwise known as Librax, is approved by the FDA for 8 uses like Enterocolitis and Irritable Bowel Syndrome .
Enterocolitis
Used to treat acute Enterocolitis in combination with Clidinium
Irritable Bowel Syndrome
Used to treat Irritable Bowel Syndrome (IBS) in combination with Clidinium
Irritable Bowel Syndrome (IBS)
Used to treat Irritable Bowel Syndrome (IBS) in combination with Clidinium
acute Enterocolitis
Used to treat acute Enterocolitis in combination with Clidinium
Depression
Used to treat Depression in combination with Amitriptyline
Peptic Ulcer Disease
Used to treat Peptic Ulcer Disease in combination with Clidinium
Anxiety
Used to treat moderate to severe anxiety in combination with Amitriptyline
moderate to severe symptoms
Used to treat moderate to severe symptoms in combination with Amitriptyline

Effectiveness

How Limbitrol Ds Affects PatientsChlordiazepoxide has calming, sleep-inducing, appetite-stimulating, and mild pain-relieving effects. It seems to stop some types of activity in the brain stem. Research has shown that it could affect the limbic system in the brain, which is involved in emotion. In one study, hostile monkeys became calmer after taking chlordiazepoxide. Other studies have found that the drug could reduce fear and aggression in rats that had been made aggressive due to brain damage. The dose of chlordiazepoxide used to reduce aggression was much lower than the dose needed to cause drowsiness.
How Limbitrol Ds works in the bodyChlordiazepoxide works by binding to certain sites in the brain, which allows it to increase the effectiveness of a neurotransmitter called GABA. This induces relaxation and reduces anxiety, as well as providing sedative and muscle-relaxing effects.

When to interrupt dosage

The suggested dosage of Limbitrol Ds is subject to the diagnosed disorder, including Syndrome, moderate to severe symptoms and Depression. The quantity of dosage is contingent upon the method of administration outlined in the table below.
Condition
Dosage
Administration
moderate to severe symptoms
, 5.0 mg, 10.0 mg, 25.0 mg
, Oral, Capsule, Capsule - Oral, Capsule, gelatin coated, Capsule, gelatin coated - Oral, Tablet, Tablet - Oral, Tablet, film coated, Tablet, film coated - Oral
Depression
, 5.0 mg, 10.0 mg, 25.0 mg
, Oral, Capsule, Capsule - Oral, Capsule, gelatin coated, Capsule, gelatin coated - Oral, Tablet, Tablet - Oral, Tablet, film coated, Tablet, film coated - Oral
Enterocolitis
, 5.0 mg, 10.0 mg, 25.0 mg
, Oral, Capsule, Capsule - Oral, Capsule, gelatin coated, Capsule, gelatin coated - Oral, Tablet, Tablet - Oral, Tablet, film coated, Tablet, film coated - Oral
Anxiety Disorders
, 5.0 mg, 10.0 mg, 25.0 mg
, Oral, Capsule, Capsule - Oral, Capsule, gelatin coated, Capsule, gelatin coated - Oral, Tablet, Tablet - Oral, Tablet, film coated, Tablet, film coated - Oral
Irritable Bowel Syndrome
, 5.0 mg, 10.0 mg, 25.0 mg
, Oral, Capsule, Capsule - Oral, Capsule, gelatin coated, Capsule, gelatin coated - Oral, Tablet, Tablet - Oral, Tablet, film coated, Tablet, film coated - Oral
Peptic Ulcer Disease
, 5.0 mg, 10.0 mg, 25.0 mg
, Oral, Capsule, Capsule - Oral, Capsule, gelatin coated, Capsule, gelatin coated - Oral, Tablet, Tablet - Oral, Tablet, film coated, Tablet, film coated - Oral
Syndrome
, 5.0 mg, 10.0 mg, 25.0 mg
, Oral, Capsule, Capsule - Oral, Capsule, gelatin coated, Capsule, gelatin coated - Oral, Tablet, Tablet - Oral, Tablet, film coated, Tablet, film coated - Oral
Anxiety
, 5.0 mg, 10.0 mg, 25.0 mg
, Oral, Capsule, Capsule - Oral, Capsule, gelatin coated, Capsule, gelatin coated - Oral, Tablet, Tablet - Oral, Tablet, film coated, Tablet, film coated - Oral
Anxiety
, 5.0 mg, 10.0 mg, 25.0 mg
, Oral, Capsule, Capsule - Oral, Capsule, gelatin coated, Capsule, gelatin coated - Oral, Tablet, Tablet - Oral, Tablet, film coated, Tablet, film coated - Oral

Warnings

There are 20 known major drug interactions with Limbitrol Ds.
Common Limbitrol Ds Drug Interactions
Drug Name
Risk Level
Description
Azelastine
Major
Chlordiazepoxide may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
Deutetrabenazine
Major
The risk or severity of sedation and somnolence can be increased when Chlordiazepoxide is combined with Deutetrabenazine.
Ethanol
Major
Chlordiazepoxide may increase the central nervous system depressant (CNS depressant) activities of Ethanol.
Methadone
Major
Chlordiazepoxide may increase the central nervous system depressant (CNS depressant) activities of Methadone.
Oliceridine
Major
The risk or severity of hypotension, sedation, death, somnolence, and respiratory depression can be increased when Chlordiazepoxide is combined with Oliceridine.
Limbitrol Ds Toxicity & Overdose RiskThe lethal dose of this drug in rats is 537mg/kg if taken orally. Overdosing on this drug may cause shallow breathing, muscle weakness, and excessive sleepiness.
image of a doctor in a lab doing drug, clinical research

Limbitrol Ds Novel Uses: Which Conditions Have a Clinical Trial Featuring Limbitrol Ds?

Currently, 794 active clinical trials are examining the potential of Limbitrol Ds in reducing moderate to severe Anxiety Disorders and related Syndromes.
Condition
Clinical Trials
Trial Phases
Anxiety Disorders
54 Actively Recruiting
Phase 2, Not Applicable, Phase 4, Phase 3, Early Phase 1
Enterocolitis
0 Actively Recruiting
Irritable Bowel Syndrome
5 Actively Recruiting
Not Applicable, Phase 2, Early Phase 1
Syndrome
4 Actively Recruiting
Phase 2, Phase 3, Not Applicable
Peptic Ulcer Disease
0 Actively Recruiting
Anxiety
1 Actively Recruiting
Not Applicable
Anxiety
0 Actively Recruiting
Depression
304 Actively Recruiting
Not Applicable, Phase 1, Phase 2, Early Phase 1, Phase 4, Phase 3
moderate to severe symptoms
0 Actively Recruiting

Limbitrol Ds Reviews: What are patients saying about Limbitrol Ds?

5Patient Review
1/12/2008
Limbitrol Ds for Anxiousness associated with Depression
4Patient Review
1/16/2010
Limbitrol Ds for Anxiousness associated with Depression
This prescription has allowed me to finally get a good night's sleep. I have Rheumatoid Arthritis, so previously it was difficult for me to even fall asleep due to discomfort. Ambien helped me fall asleep but I would always wake up after a few hours. This medication keeps me asleep for around 7 hours, which is great!
3Patient Review
3/15/2010
Limbitrol Ds for Osteoporosis
This treatment really helped me. I'm grateful for modern medicine.
2.3Patient Review
3/20/2013
Limbitrol Ds for Anxiousness associated with Depression
I felt okay the first week, but then began to experience increased levels of depression and anxiety. These nightmares and thoughts were really terrible, so I stopped taking the medication. I changed my diet and started working out, which made me feel a lot better. A year later and I'm doing things I never thought possible- like rock climbing with friends.
image of drug pills surrounding a glass of water symbolizing drug consumption

Patient Q&A Section about limbitrol ds

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Do they still make Limbitrol?

"The Limbitrol brand name has been discontinued in the U.S. Generic versions of the product have been approved by the FDA and may be available."

Answered by AI

What are the side effects of Limbitrol?

"The following effects may occur: drowsiness, dizziness, dry mouth, blurred vision, constipation, bloating, trouble urinating, and weight gain. If you experience any of these effects, tell your doctor or pharmacist. To reduce the risk of dizziness or fainting, stand up slowly when you get up from a sitting or lying position."

Answered by AI

What is Limbitrol prescribed for?

"The drug LIMBITROL is indicated for the treatment of patients who have moderate to severe depression along with moderate to severe anxiety. The drug tends to work faster and with fewer treatment failures than when either amitriptyline or chlordiazepoxide are used alone."

Answered by AI

Clinical Trials for Limbitrol Ds

Image of Stanford Digestive Health Clinic in Redwood City, United States.

MITI-001 for Irritable Bowel Syndrome

18 - 65
All Sexes
Redwood City, CA
While the pathophysiology of diarrhea-predominant irritable bowel syndrome (IBS-D) is complex and heterogeneous, dysbiosis of the gut microbiome is frequently observed, suggesting that a substantial subset of patients with irritable bowel syndrome (IBS) have symptoms that are initiated and/or perpetuated by a microbiome dysfunction. Successful randomized controlled trials (RCT) for IBS-D (Ford 2018; Black 2022) leveraging microbiome-targeted therapies (antibiotics or low microbiome fermentation diets) suggest the gut microbiome is at least partially involved in IBS symptoms. Furthermore, fecal microbiota transplantation (FMT) for patients with IBS-D has demonstrated promising results (El-Salhy 2020), supporting the possibility that altering the microbiome composition could ameliorate IBS-D symptoms. MITI-001 is a transplantable gut bacterial community composed of 157 live bacterial strains, encompassing 79 genera of commensal bacteria, that have been isolated from healthy donor stool, purified, and banked. The hypothesis of the proposed research is that MITI-001 can target the pathophysiologic lesion in a subset of IBS-D patients, restore the altered microbial metabolic process, and thus alleviate IBS-D symptoms.
Phase < 1
Waitlist Available
Stanford Digestive Health Clinic (+1 Sites)Sean P Spencer, MD, PhD
Image of Cedars-Sinai Medical Center in Los Angeles, United States.

Living Well Program for Anxiety in Breast Cancer

18+
Female
Los Angeles, CA
The goal of this study is to evaluate the efficacy and cost-effectiveness of the Living Well Program, a digital therapeutic application with telecoaching support, in breast cancer patients with moderate-to-severe anxiety. The main question the study aims to answer is: does digital cognitive-behavioral therapy-based interventions decrease the overall healthcare costs of patients with stage II to IV breast cancer? The study has one group of participants who will use the Living Well app and telecoaching support. This group will be compared to retroactively matched controls. Over 3 months, patients will complete 21 mental health modules and 5 telecoaching sessions. In the following 3 months, they will complete any outstanding telecoaching sessions and modules while still being monitored, even if they finished all modules and sessions in the first 3 months. The 6 months after that will be the follow-up phase. They will still have access to the Living Well app and may continue to use it, and they will complete the same assessment questionnaires as baseline to identify any changes in their overall mental health.
Waitlist Available
Has No Placebo
Cedars-Sinai Medical CenterScott Irwin, MD
Image of University of California San Diego in La Jolla, United States.

AI Chatbot for Postpartum Loneliness

18+
Female
La Jolla, CA
The goal of this clinical trial is to learn whether a postpartum chatbot powered by generative artificial intelligence (genAI) can help new mothers get better pelvic floor health information and feel less lonely after childbirth. The main questions this study aims to answer are: * Does using the chatbot improve postpartum pelvic floor health knowledge? * Does using the chatbot help reduce feelings of loneliness during the postpartum period? * Does using the chatbot impact pelvic floor symptoms? Researchers will compare standard postpartum care to standard care plus the chatbot. Participants will: Be assigned by chance (like flipping a coin) to standard postpartum care with or without access to the chatbot. If in the chatbot group, participants will receive education and support via the chatbot over a 4-week period. Both groups will complete questionnaires to measure their pelvic floor knowledge, pelvic floor symptoms, feelings of loneliness, depression, infant bonding, perceived social support, adverse childhood experiences, and peri-traumatic distress. The chatbot was created by urogynecology experts in collaboration with UC San Diego computer science and biomedical informatics researchers. The chatbot is designed to give new mothers personalized, evidence-based information and support in real time.
Waitlist Available
Has No Placebo
University of California San Diego
Have you considered Limbitrol Ds clinical trials? We made a collection of clinical trials featuring Limbitrol Ds, we think they might fit your search criteria.Go to Trials
Image of Virtual/ No Physical Facility in Palm City, United States.

Akashic Records Sessions for Mental Health

18+
All Sexes
Palm City, FL
The goal of this clinical study is to learn the impact of two Akashic Records sessions on mental health symptoms in adults. We want to see how sessions are linked to stress, anxiety, and depression, and to resilience (ability to bounce back) and feelings of connectedness (to self, community, and humanity). Main questions this study will answer are: After two sessions, what is the impact on stress, anxiety, and depression? After two sessions, what is the impact on resilience and connectedness? How do participants describe their experience of the sessions? After two sessions, what are participants' views of their problems (insight), emotional experiences (impact) and observable behaviors in their daily life? What participants will do: Complete online surveys about their mood at four points: before the first session, before the second session, after the second session, and again 2 months later. Surveys include: DASS-21 (Depression, Anxiety, and Stress Scale) CD-RISC-10 (Connor-Davidson Resilience Scale) WATTS (Connectedness Scale) A short demographic form and satisfaction survey Attend two individual Akashic Records sessions (50-90 minutes each) over private video platform with a licensed clinical social worker (principal investigator) The first 50 participants will also join a one-hour interview with open ended questions with a licensed clinical social worker (co-investigator) about one week after the second session to share their experience in their own words. Who can take part: Adults ages 18 and older who can read and consent in English and who have experienced stress, anxiety, or low mood in the past year. How the research will happen: Sessions are held by secure video call. Participants will also complete private online surveys before, during, and after the sessions. Some participants may be invited to share their experiences in a one-on-one interview. All information is kept private and names are removed before analysis. Risks and benefits: Talking about personal topics may bring up strong emotions. Licensed clinicians conduct sessions, offer support, and provide referrals if needed. Possible benefits include new insights, greater peace or meaning, and improved coping; benefits are not guaranteed. Why this matters: Many people seek spiritual or transpersonal support for emotional concerns. This pilot study will provide early evidence on whether Akashic Records sessions may be a helpful, low-risk option and will guide future research.
Waitlist Available
Has No Placebo
Virtual/ No Physical FacilityCandice S Rasa, LCSW
Image of University of California, Los Angeles in Los Angeles, United States.

Virtual Reality Reward Training for Depression

18+
All Sexes
Los Angeles, CA
The purpose of this study is to compare the effects of enhanced Virtual Reality-Reward Training (eVR-RT) with an active control condition, Virtual Reality-Memory Training (VR-MT), on positive affect and other clinical symptoms. Enhanced VR-Reward Training is a novel intervention aimed at enhancing savoring of positive experiences among individuals with depression and low positive affect through guided imaginal recounting following immersion in positive VR experiences. The current study tests an enhanced version of this training using improved virtual reality technology. Target enrollment is 80 participants with low positive affect, depression, and impaired functioning, who are at least 18 years old, who will be randomly assigned to 7 weeks of either enhanced Virtual Reality-Reward Training (VR-RT) or Virtual Reality-Memory Training (VR-MT). Participants will complete in-person VR sessions, laboratory assessments, self-report questionnaires as part of the study. A subset of 8 participants randomly assigned to VR-RT will complete fMRI scans and EMA surveys. The total length of participation is around 3 months.
Phase 2
Recruiting
University of California, Los Angeles
Have you considered Limbitrol Ds clinical trials? We made a collection of clinical trials featuring Limbitrol Ds, we think they might fit your search criteria.Go to Trials
Image of Syracuse VA Medical Center, Syracuse, NY in Syracuse, United States.

Self-Help Intervention for Depression and PTSD

18+
All Sexes
Syracuse, NY
It is important to provide support and resources for the many post-9/11 Veterans with mental health symptoms and poor psychosocial functioning who do not engage in psychotherapy. One of the biggest reasons post-9/11 Veterans do not seek treatment is a preference to handle problems on their own. This study examines a self-help intervention that teaches Veterans healthy coping strategies they can use on their own and how to seek out recovery support services such as mental health treatment or whole-person care if they decide to do so in the future. This study will compare the impact of self-help and standard resources at improving mental health and resource utilization. Two hundred Veterans will complete 6 brief assessments across 40 weeks.
Waitlist Available
Has No Placebo
Syracuse VA Medical Center, Syracuse, NY (+1 Sites)Robyn L. Shepardson, PhD
Image of Massachusetts General Hospital in Boston, United States.

Online Parent Education for Child Anxiety

18+
All Sexes
Boston, MA
The investigators are doing this research to test whether parents of children ages 2-7 can better manage their child's anxiety by completing a brief, online, self-guided parent education program. One way to provide anxiety management skills to more children, and to potentially prevent worsening outcomes, is to offer online and self-guided educational programs that parents can complete without a clinician. This randomized trial will evaluate the effects of two brief, online, self-guided parent education programs designed to improve parents' understanding of anxiety and teach parents way to help their children cope with anxiety. Parents will be randomly assigned to one of the three programs. The main aim of the study is to examine whether the parent programs, compared to an educational control reduce parental accommodation of anxiety across a 1-, 4-, and 8-month follow-up period. As a secondary aim, the investigators will explore whether the parent programs reduce children's anxiety symptoms over the 8-month follow-up period. Results will inform the development of a scalable, low-cost model for promoting access to evidence-based treatment to young children.
Recruiting
Online Trial
Massachusetts General Hospital
Have you considered Limbitrol Ds clinical trials? We made a collection of clinical trials featuring Limbitrol Ds, we think they might fit your search criteria.Go to Trials
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security